Silo Pharma (SILO)
Licenses preclinical CNS therapies while building QwikAgents and a cryptocurrency treasury.
Something off on this page? Send us feedback.
Licenses and develops preclinical CNS therapies, with reported revenue from license-fee recognition and prospective income from therapeutic rights, QwikAgents subscriptions, and digital-asset staking. Its lean model relies on outside IP and research partners.
Licenses and advances central-nervous-system drug candidates, led by SPC-15, a preclinical intranasal therapy for PTSD and stress-induced anxiety. The portfolio also includes SP-26, a time-release ketamine implant for fibromyalgia and chronic pain, and SPC-14 for Alzheimer’s-related symptoms. QwikAgents is a managed AI-agent platform being prepared for commercial launch, while a cryptocurrency treasury holds and stakes digital assets.
Operates from Florida through a lean, partner-dependent model: Columbia supplies core therapeutic rights, Medspray supplies nasal-delivery technology, and universities, CROs, manufacturers, and consultants perform much of the development work. Drug candidates have not produced commercial product revenue and remain dependent on clinical development and regulatory authorization; the licensing arrangements carry fees, milestones, royalties, and termination conditions.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.4M · Total debt $0 · Total assets $6.0M · Shareholders' equity $4.9M
- Revenue
- $0
- Operating income
- −$928.9K
- Net income
- −$832.8K
No dividends on record.
| Institutions14 holders · as of Mar 31, 2026 | 6.24% | 70.4K shares | |
| Insiders1 holder · as of Dec 16, 2025 | 1.28% | 14.5K shares | |
| Otherremainder | 92.48% | 1.04M shares |
1.13M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (1.59M in the company's Sep 3, 2026 report, 1.13M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
AdvisorShares TrustInstitution | 6.70% | 75,582 | 13Gfiled Jul 8, 2026 ↗ |
Advisorshares Investments LLCInstitution | 3.92% | 663,965 | 13Fas of Mar 31, 2026 |
Eric WeisblumInsiderdirector, officer: Chief Executive Officer | 1.28% | 14,462 | Form 4filed Dec 16, 2025 ↗ |
Geode Capital Management, LLCInstitution | 1.06% | 180,031 | 13Fas of Mar 31, 2026 |
Susquehanna International Group, LLPInstitution | 0.37% | 62,795 | 13Fas of Mar 31, 2026 |
| See all 21 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 15, 2025 | Eric Weisblum | director, officer: Chief Executive Officer | +5,000 | $0.4150 |
| Nov 20, 2025 | Eric Weisblum | director, officer: Chief Executive Officer | +1,000 | $0.3700 |
| Nov 21, 2025 | Eric Weisblum | director, officer: Chief Executive Officer | +1,000 | $0.3650 |
| Nov 18, 2025 | Eric Weisblum | director, officer: Chief Executive Officer | +7,500 | $0.4033 |
| Nov 19, 2025 | Eric Weisblum | director, officer: Chief Executive Officer | +4,500 | $0.4050 |
- Microsoft
Enterprise AI-agent platform with major distribution advantages.
- Tonix Pharmaceuticals
Approved fibromyalgia therapy ahead of a preclinical alternative.
- Alphabet Class A
Cloud AI-agent platform for building, deploying, and governing agents.
- Salesforce
Enterprise agent platform embedded in CRM and customer workflows.
- Eli Lilly
Approved Alzheimer's therapy occupying early-disease treatment pathways.
- Biogen
Co-commercializer of a marketed early Alzheimer's therapy.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Silo Pharma | $2.49 | −2.92% | $2.8M | — | — | 52.2 | — |
| Microsoft | $498.00 | +0.24% | $3.69T | 27.7 | 25.4 | 11.1 | +17.8% |
| Tonix Pharmaceuticals | $13.38 | 0.00% | $213.3M | — | — | 7.3 | +577.9% |
| Alphabet Class A | $338.45 | +0.39% | $4.08T | 16.9 | 25.1 | 9.2 | +24.2% |
| Salesforce | $259.76 | +1.09% | $210.43B | 23.4 | 17.6 | 4.8 | +10.8% |
| Eli Lilly | $1,164.64 | +0.45% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Biogen | $222.65 | −0.03% | $32.90B | 39.4 | 16.8 | 3.3 | +3.4% |
| Median | 27.7 | 25.1 | 8.2 | +21.0% |